- This meta-analysis found no evidence for a glucosamine effect on pain or function in osteoarthritis (OA), including in any prespecified patient subgroups.
- Open access to trial data remains a largely unmet goal.
Why this matters
- Evidence for glucosamine’s benefits in OA is weakening as better quality studies emerge.
- Whether a greater or lesser effect might appear in patient subgroups is unknown.
- 6 trials agreed to share data (5 using placebo control were analyzed).
- 4 trials were of knee OA and 1 of hip OA (n=1625).
- All studies had low risk for bias.
- No outcome measure revealed a statistically significant difference between glucosamine and placebo in any subgroup.
- Results were unchanged when analyzed for 4 knee OA trials (n=1403).
- Meta-analysis of individual patient data on efficacy of oral glucosamine for knee, hip OA in predefined subgroups.
- Subgroups based on pain, BMI, inflammation.
- Researchers requested shared trial data from 21 randomized controlled trials from 1994 to 2014 in the OA Trial Bank.
- Primary outcome: Pain severity during 3-6 mo and at ≥1 y follow-up.
- Funding: Dutch Arthritis Foundation.
- Few trials' data available.
- Many missing data in outcome measures of analyzed trials.